IPO Year: 2025
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/8/2026 | $37.00 | Buy | Needham |
| 4/7/2026 | Buy | TD Cowen | |
| 3/19/2026 | $35.00 | Buy | Canaccord Genuity |
| 11/21/2025 | $34.00 | Overweight | Morgan Stanley |
| 11/21/2025 | $28.00 | Buy | Stifel |
| 11/21/2025 | $32.00 | Buy | Jefferies |
| 11/21/2025 | $30.00 | Outperform | Leerink Partners |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Needham initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $37.00
TD Cowen initiated coverage of MapLight Therapeutics with a rating of Buy
Canaccord Genuity initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $35.00
Morgan Stanley initiated coverage of MapLight Therapeutics with a rating of Overweight and set a new price target of $34.00
Stifel initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $28.00
Jefferies initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $32.00
Leerink Partners initiated coverage of MapLight Therapeutics with a rating of Outperform and set a new price target of $30.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
Fastest customizable press release news feed in the world
Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004 for autism spectrum disorder has completed enrollment, with topline results expected in the third quarter of 2026Received FDA Fast Track designation for ML-007C-MA for Alzheimer's disease psychosis; topline results from Phase 2 VISTA trial expected in the second half of 2027Expanded pipeline with a next-generation M1/M4 muscarinic agonist program, ML-055, with candidate nomination expected in 2026Ended the year with $453.1 million in cash, cash equivalents and investments, which is expected to f
SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2026 Biotech on the Beach Summit (Miami, FL)Date: Tuesday, March 10thFormat: Hosting 1x1 meetings Event: Leerink 2026 Global Healthcare Conference (Miami, FL)Date: Wednesday, March 11thFormat: Presenting and hosting 1x1 meetings Event: Stifel 2026 Virtual CNS ForumDate: Wednesday, March 18thFormat: Presenting and hosting 1x1 meetings Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the "Events & P
SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (NASDAQ:MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company's Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis. "The accelerated enrollmen
SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. ("MapLight") (NASDAQ:MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The Fast Track process is intended to facilitate the development and expedite the review of investigational therapies for serious conditions with unmet medical need. A drug with Fast Track designation may be eligible for more frequent interactions with the FDA, as well as accelerated approval and priority review
SAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (NASDAQ:MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies targeting a novel G protein-coupled receptor (GPCR) for the treatment of central nervous system (CNS) disorders. Under the terms of the agreement, SandboxAQ received an upfront payment and will be eligible to receive additional preclinical, development, regulatory, and commercial milestone payments of up to $200 million in aggregate. The companies will jointly conduct preclinical research activities and MapLight will have exclusive rights
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's disease psychosis expected in the second half of 2027Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025Cash, cash equivalents and short-term investments sufficient to fund operations through 2027 SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system diso
SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced the closing of its initial public offering of 16,962,500 shares of common stock at an initial public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 2,212,500 shares of common stock. In addition to the shares sold in the initial public offering, MapLight announced the closing of the concurrent sale of 476,707 shares of common stock at the initial public of
144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
144/A - MapLight Therapeutics, Inc. (0001770069) (Subject)
144/A - MapLight Therapeutics, Inc. (0001770069) (Subject)
144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
S-8 - MapLight Therapeutics, Inc. (0001770069) (Filer)
10-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
10-Q - MapLight Therapeutics, Inc. (0001770069) (Filer)